Table 4 Multivariate survival analysis of combinatory LINE-1 methylation level and lymphatic embolus status and clinicopathological parameters with respect to overall survival
Parameters | Hazard ratio (95% C.I.) | P-value | |
|---|---|---|---|
LINE-1 methylation /lymphatic emboli status | 0.001 | ||
High/absent (n = 58) | Reference | ||
Low/present (n = 28) | 3.128 (1.523–6.424) | 0.002 | |
Low/absent (n = 44) | 1.113 (0.460–2.695) | 0.812 | |
High/present (n = 42) | 0.761 (0.237–2.443) | 0.647 | |
Gross type | 0.073 | ||
Mass forming (n = 141) | Reference | ||
Periductal infiltrative (n = 8) | 0 | 0.972 | |
Intraductal growth (n = 18) | 0.141 (0.019–1.032) | 0.054 | |
Mixed (n = 5) | 3.013 (0.885–10.254) | 0.078 | |
T staging | 0.152 | ||
pT1 (n = 48) | Reference | ||
pT2 (n = 52) | 0.579 (0. 220–1.526) | 0.270 | |
pT3 (n = 47) | 0.371 (0.124–1.114) | 0.077 | |
pT4 (n = 25) | 0.233 (0.056–0.971) | 0.046 | |
N staging | pN0 (n = 133) | ||
pN1 (n = 39) | 2.456 (1.341–4.497) | 0.004 | |
Perineural invasion | Absent (n = 118) | ||
Present (n = 54) | 0.321 (0.147–0.699) | 0.004 | |
Differentiation | 0.577 | ||
Well (n = 23) | Reference | ||
Moderate (n = 94) | 3.495 (0.332–36.809) | 0.298 | |
Poor (n = 55) | 3.493 (0.328–37.217) | 0.300 |